GDC-1971: SHP2 Inhibitor Ushering in a New Era of Cancer Treatment
In recent years, protein tyrosine phosphatase SHP2 has become a highly regarded research target in the field of oncology in mediating the RAS-driven MAPK signaling pathway. Its treatment methods are not limited to single drug use, but also can work together with KRAS inhibitors, showing good ...
危险品化学品经营许可证（带存储）